AV5124 / Viriom - LARVOL DELTA

Synthesis, inhibitory activity and oral dosing formulation of AV5124, the structural analogue of influenza virus endonuclease inhibitor baloxavir. (PubMed, J Antimicrob Chemother) - "Overall, AV5124 and A5116 are promising inhibitors of the influenza virus CEN and warrant further development as potent anti-influenza agents."

Journal • Infectious Disease • Respiratory Diseases

Viriom donates Elpida to Chinese and Russian governments for experimental use against COVID-19; also working with global health authorities to determine the efficacy and safety of Elpida and its other clinical candidates AV5080, AV5124 and AV5126 against Covid-19 (PRNewswire) - "Viriom Inc today announces...experimental use of the HIV medicine, Elpida (elsulfavirine) and Viriom's experimental flu medicines AV5080, AV5124 and AV5126 to determine their efficacy in the treatment of COVID-19....The company is collaborating with Chinese Center for Disease Control and Prevention and the Ministry of Health in Russia and select health authorities and institutions in US and globally....Viriom is collaborating with PLA Military Academy and Zhejiang University in China, ChemRar Group, Gamaleya Research Institute of Epidemiology and Microbiology, Research Center Institute of Immunology in Russia, Osang Healthcare in South Korea to support research of targeted medicines with novel mechanisms of action against COVID-19 and other pathogenic RNA viruses."

Licensing / partnership